Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.

8 In the multivariable Cox model reported by Ruhwedel et al., the overall effect of primary tumor location was not statistically significant ( p = .11), but there was a nominally significant association for shorter OS in patients with pancreatic versus gastrointestinal NETs during [ 177 Lu]Lu‐edotreotide therapy ( p = .04). 33 However, there are prognostic differences between NETs of different origin, depending on the aggressiveness of disease. 44 , 45 Overall, our findin

also in 2,357 other papers